⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Corbus Pharmaceuticals Holdings, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Corbus Pharmaceuticals Holdings, Inc.
↗Norwood, Massachusetts, USA
Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for oncology and obesity. The company leverages deep biological insights to target well-understood pathways, aiming to transform patient outcomes in areas of high unmet medical need.
Its current development pipeline is anchored by two primary assets: CRB-701, a next-generation antibody-drug conjugate (ADC) targeting Nectin-4 for solid tumors, and CRB-913, a peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. The company is transitioning from early clinical development toward registrational-stage studies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$0M
Founded:2009
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:CRBP
Market Cap:$0.15B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3 (CRB-701)
Modalities:Antibody-drug conjugate (ADC), Monoclonal antibody, Small molecule
Active Trials:2
Trial Phases:Phase 1: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:CSPC Pharmaceutical Group (Licensing agreement for CRB-701/SYS6002)
COMPETITION
Position:Emerging
Competitors:Capricor Therapeutics, CytomX Therapeutics, Geron
LEADERSHIP
Key Executives:
Yuval Cohen - CEO
Nishant Saxena - Chief Business Officer
Sean Moran - Chief Financial Officer
Board Members:Rachelle Jacques (Chair), Brent Pfeiffenberger, Anne Altmeyer, Yong Ben
LINKS
Website:corbuspharma.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Corbus Pharmaceuticals Holdings, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.